Exelixis (EXEL) Capital Expenditures Growth (3y) (2013 - 2026)
Exelixis (EXEL) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Exelixis | 14.60 Bn | 13.82 Bn | 590.86 Mn | -49.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -49.93% |
| Jan 2, 2026 | -50.80% |
| Oct 3, 2025 | -33.52% |
| Jul 4, 2025 | -27.14% |
| Apr 4, 2025 | -19.26% |
| Jan 3, 2025 | -56.73% |
| Sep 27, 2024 | 31.74% |
| Jun 28, 2024 | -31.24% |
| Mar 29, 2024 | -10.59% |
| Dec 29, 2023 | -19.06% |
| Mar 31, 2023 | 59.54% |
| Sep 30, 2022 | 34.80% |
| Jul 1, 2022 | 82.40% |
| Apr 1, 2022 | 34.47% |
| Dec 31, 2021 | 54.08% |
| Oct 1, 2021 | -43.28% |
| Jul 2, 2021 | 71.65% |
| Apr 2, 2021 | 27.07% |
| Jan 1, 2021 | 5.83% |
| Apr 3, 2020 | 438.14% |